Shattuck Labs Crecimiento futuro

Future controles de criterios 2/6

Shattuck LabsSe prevé que los beneficios de la empresa disminuyan en 16.1% al año, mientras que sus ingresos anuales crecerán en 34.1% al año. Se prevé que el BPA se sitúe en decline a una tasa anual de 2.6%. Se prevé que la rentabilidad de los fondos propios sea de -176.8% en 3 años.

Información clave

-14.8%

Tasa de crecimiento de los beneficios

-0.5%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Biotechs	20.7%
Tasa de crecimiento de los ingresos	63.1%
Rentabilidad financiera futura	-47.0%
Cobertura de analistas	Low
Última actualización	11 Apr 2024

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Shattuck Labs, Inc. (NASDAQ:STTK) Just Reported And Analysts Have Been Cutting Their Estimates

Mar 18

Is Shattuck Labs (NASDAQ:STTK) In A Good Position To Deliver On Growth Plans?

Feb 25

Will Shattuck Labs (NASDAQ:STTK) Spend Its Cash Wisely?

Nov 23

We Think Shattuck Labs (NASDAQ:STTK) Can Afford To Drive Business Growth

Aug 24

Shattuck Labs names Abhinav Shukla as chief technical officer

Jun 01

Shattuck Labs EPS beats by $0.11, beats on revenue

May 10

Here's Why We're Not Too Worried About Shattuck Labs' (NASDAQ:STTK) Cash Burn Situation

May 07

Could The Shattuck Labs, Inc. (NASDAQ:STTK) Ownership Structure Tell Us Something Useful?

Mar 08

We're Hopeful That Shattuck Labs (NASDAQ:STTK) Will Use Its Cash Wisely

Jan 12

Shattuck Labs reports Q3 results

Nov 13

Previsiones de crecimiento de beneficios e ingresos

NasdaqGS:STTK - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2026	N/A	-167	-179	N/A	3
12/31/2025	N/A	-108	-129	N/A	4
12/31/2024	1	-92	-103	N/A	5
12/31/2023	2	-87	-82	-81	N/A
9/30/2023	1	-95	-87	-86	N/A
6/30/2023	1	-92	-99	-97	N/A
3/31/2023	1	-98	-104	-95	N/A
12/31/2022	1	-102	-106	-94	N/A
9/30/2022	30	-69	-102	-89	N/A
6/30/2022	32	-61	-87	-74	N/A
3/31/2022	28	-58	-80	-72	N/A
12/31/2021	30	-45	-65	-57	N/A
9/30/2021	1	-65	-59	-52	N/A
6/30/2021	2	-59	-56	-51	N/A
3/31/2021	9	-42	-38	-34	N/A
12/31/2020	10	-37	-34	-34	N/A
9/30/2020	11	-32	-28	-27	N/A
6/30/2020	11	-27	-24	-23	N/A
3/31/2020	10	-26	-29	-28	N/A
12/31/2019	10	-24	-21	-21	N/A
12/31/2018	22	-7	-8	-7	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: STTK se prevé que siga sin ser rentable en los próximos 3 años.

Beneficios vs. Mercado: STTK se prevé que siga sin ser rentable en los próximos 3 años.

Beneficios de alto crecimiento: STTK se prevé que siga sin ser rentable en los próximos 3 años.

Ingresos vs. Mercado: STTKSe prevé que los ingresos de la empresa (34.1% al año) crezcan más deprisa que los del mercado US (8.1% al año).

Ingresos de alto crecimiento: STTKSe prevé que los ingresos de la empresa (34.1% al año) crezcan más deprisa que 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: STTK se prevé que no sea rentable en 3 años.

Descubre empresas en crecimiento

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Shattuck Labs Crecimiento futuro

Future controles de criterios 2/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Consensus revenue estimates increase by 170%

Price target increased by 21% to US$15.50

Consensus revenue estimates increase by 78%, EPS downgraded

Consensus revenue estimates increase by 16%

Price target decreased by 21% to US$12.80

Consensus revenue estimates decrease by 11%

Recent updates

Consensus revenue estimates increase by 170%

General Counsel notifies of intention to sell stock

Insufficient new directors

Shattuck Labs, Inc. Announces Board Appointments

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Chief Financial Officer recently sold US$250k worth of stock

Chief Financial Officer notifies of intention to sell stock

Shattuck Labs, Inc. has filed a Follow-on Equity Offering in the amount of $30.000001 million.

New minor risk - Shareholder dilution

Shattuck Labs, Inc. has filed a Follow-on Equity Offering in the amount of $30.000001 million.

Price target increased by 21% to US$15.50

New major risk - Financial position

Consensus revenue estimates increase by 78%, EPS downgraded

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Shattuck Labs, Inc. to Report Q3, 2023 Results on Nov 09, 2023

Shattuck Labs, Inc. to Present Topline Data from Phase 1 A/B Clinical Trial of Sl-172154 in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (Aml) and Higher-Mds) Patients At the American Society of Hematology (Ash) 2023 Annual Meeting

Consensus revenue estimates increase by 16%

Price target decreased by 21% to US$12.80

Consensus revenue estimates decrease by 11%

Consensus revenue estimates increase by 91%

New minor risk - Market cap size

Can Shattuck Labs (NASDAQ:STTK) Afford To Invest In Growth?

New minor risk - Share price stability

Consensus EPS estimates upgraded to US$2.03 loss

We're Keeping An Eye On Shattuck Labs' (NASDAQ:STTK) Cash Burn Rate

Full year 2022 earnings: EPS in line with analyst expectations despite revenue beat

Shattuck Labs, Inc. to Report Q4, 2022 Results on Feb 23, 2023

Consensus forecasts updated

Is Shattuck Labs (NASDAQ:STTK) In A Good Position To Invest In Growth?

Consensus revenue estimates increase by 264%

High number of new directors

Third quarter 2022 earnings released: US$0.58 loss per share (vs US$0.41 loss in 3Q 2021)

Shattuck Labs, Inc. to Report Q3, 2022 Results on Nov 08, 2022

Second quarter 2022 earnings released: US$0.65 loss per share (vs US$0.56 loss in 2Q 2021)

Shattuck Labs GAAP EPS of -$0.65 misses by $0.06

We're Not Very Worried About Shattuck Labs' (NASDAQ:STTK) Cash Burn Rate

Shattuck Labs, Inc.(NasdaqGS:STTK) dropped from Russell 2000 Growth Index

First quarter 2022 earnings: EPS in line with expectations, revenues disappoint

Price target decreased to US$25.50

High number of new directors

Shattuck Labs, Inc., Annual General Meeting, Jun 07, 2022

Shattuck Labs Presents Preclinical Data At the 2022 American Association for Cancer Research (AACR) Annual Meeting

Consensus forecasts updated

Consensus forecasts updated

Shattuck Labs, Inc. (NASDAQ:STTK) Just Reported And Analysts Have Been Cutting Their Estimates

Price target decreased to US$39.00

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Is Shattuck Labs (NASDAQ:STTK) In A Good Position To Deliver On Growth Plans?

Rosen Law Firm Files Securities Class Action Lawsuit Against Shattuck Labs, Inc

Lead Independent Director recently bought US$56k worth of stock

Will Shattuck Labs (NASDAQ:STTK) Spend Its Cash Wisely?

Chief Financial Officer exercised options to buy US$250k worth of stock.

Third quarter 2021 earnings released: US$0.41 loss per share (vs US$1.54 loss in 3Q 2020)

High number of new and inexperienced directors

General Counsel notifies of intention to sell stock

We Think Shattuck Labs (NASDAQ:STTK) Can Afford To Drive Business Growth

Consensus revenue estimates fall to US$2.31m

General Counsel notifies of intention to sell stock

General Counsel notifies of intention to sell stock

Shattuck Labs names Abhinav Shukla as chief technical officer

Co-Founder & Chairman of the Board notifies of intention to sell stock

Co-Founder & Chairman of the Board notifies of intention to sell stock

First quarter 2021 earnings released: US$0.28 loss per share (vs US$0.86 loss in 1Q 2020)

Shattuck Labs EPS beats by $0.11, beats on revenue

Here's Why We're Not Too Worried About Shattuck Labs' (NASDAQ:STTK) Cash Burn Situation

Chief Financial Officer notifies of intention to sell stock

Chief Financial Officer notifies of intention to sell stock

Shattuck Labs, Inc. Promotes Andrew R. Neill to Chief Financial Officer

Full year 2020 earnings released: US$2.36 loss per share (vs US$3.17 loss in FY 2019)